Capmatinib

136 interactions 289 cited references

Also sold as: Tabrecta Tabrecta®

About Capmatinib

Capmatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Capmatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread… Read the full Capmatinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Rubella Virus Vaccine, Live Typhoid Vaccine Bacillus Of Calmette And Guerin Vaccine, Live Varicella Virus Vaccine, Live Smallpox Monkeypox Vaccine Yellow Fever Vaccine

11 Contraindicated 120 Major 5 Moderate

All (136) Contraindicated (11) Major (120) Moderate (5)

Contraindicated

Capmatinib Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Capmatinib Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Capmatinib Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Capmatinib Fezolinetant Increased fezolinetant exposure Details Capmatinib Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Capmatinib Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Capmatinib Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Capmatinib Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Capmatinib Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Capmatinib Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Capmatinib Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details

Major

Capmatinib Abametapir Increased exposure of CYP3A4 substrate Details Capmatinib Relugolix Orgovyx Increased relugolix exposure Details Capmatinib Colchicine Colcrys Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Aliskiren Tekturna Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Capmatinib Apixaban Eliquis Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Betrixaban Bevyxxa® Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Afatinib Gilotrif Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Capmatinib Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Capmatinib Alosetron Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Apalutamide Erleada Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Avacopan Tavneos Increased CYP3A4 substrate exposure Details Capmatinib Bosentan Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Carbamazepine Carbatrol Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Cenobamate Xcopri Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Cholera Vaccine Ipol An increased risk of infection by the live vaccine Details Capmatinib Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Capmatinib Clomipramine Anafranil Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Clozapine Clozaril Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Conivaptan Vaprisol Increased CYP3A substrate exposure Details Capmatinib Cyclosporine Atopica Increased cycloSPORINE exposure Details Capmatinib Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Capmatinib Darolutamide Nubeqa Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Digoxin Cardoxin® Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Dofetilide Tikosyn Increased exposure of MATE1 and MATE2K substrates and risk of increased adverse reactions Details Capmatinib Doxorubicin Adriamycin Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Doxorubicin Hydrochloride Liposome Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Duloxetine Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.